Kornimate/medical-research-clean huggingface dataset:
the effect of lersivirine (uk-453,061) on qt intervals in healthy subjects

Conditions: Healthy Volunteers

Summary: this study has been designed to investigate the effect of lersivirine on the qt/qtc interval in order to help establish the safety profile of lersivirine.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years, inclusive, (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, normal 12-lead ecg and clinical laboratory tests) exclusion criteria: * history of risk factors for qt prolongation or torsades de pointes (eg, organic heart disease, congestive heart failure, hypokalemia, hypomagnesemia, congenital long qt syndrome, myocardial ischemia or infarction). * use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day * use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication.

Keywords: lersivirine qt qtc ecg hiv nnrti
role of positron emission tomography/ computed tomography (pet/ct) and in bone metastases.

Conditions: Bone Metastases

Summary: the aim of this study is to detect bone metastases by pet/ct examination in cancer patients.

bone is a fertile soil for dissemination of metastatic tumor cells which can cause either osteolytic ( destructive) or osteoblastic (sclerotic) or mixed lesions in advanced cancer. bone metastases are most common throughout the axial skeleton, this leads to major complications referred to as skeletal-related events (sres), the most frequently are the need for radiotherapy and pathological fractures, associated with increase life morbidity and decrease overall survival. seeking accurate image modalities provides definite staging, determining the optimal strategy of treatment and precise evaluation to decrease the burden of complication. pet/ct is superior than 2-dimensional planar providing a better image quality and enables quantitation of tumor metabolism. acquisition and fusion of pet with ct also allow for localization and morphologic evaluation of abnormalities, leading to increased specificity. the national comprehensive cancer network (nccn) guideline recommended pet/ct imaging in cancers with high risk skeletal metastases, pet has advantage than ct in diagnosing osteolytic lesions; but combining pet with ct, increase the detection of osteoblastic lesions. ct is recommended to evaluate structural integrity in revealing cortical integrity and the extent of structural destruction.

Eligibility criteria:
inclusion criteria: * patients diagnosed with different types of malignant tumor, suspected or diagnosed to have bone metastases and will do pet/ct examination * patients diagnosed with different types of malignant tumor, with accidently discovered bone metastases during pet/ct examination. * patients conscious to provide informed consent. exclusion criteria: * pregnant women. * patients with blood sugar \> 200 mg/dl. * patients unable to sleep in a fixed position for 20 minutes. * severely ill patients who aren't capable of complying with study procedures or comatose patients.
the effect of the use of a videolaryngoscope and/or stylet on intubation time in obese patients

Conditions: Intubation Time

Summary: although many researchers would agree that obesity per se is not a risk factor for difficult intubation, there are many well known obesity-related challenges in airway management including difficulty with mask ventilation, more frequent and rapid oxygen desaturation, increased oxygen consumption, and increased sensitivity to the respiratory depressant effects of anesthetic and analgesic drugs. hence, in these conditions, rapid and nontraumatic intubation gain higher interest. there is controversy about using videoaryngoscopy (vl) in obese patients in these difficult situations. the primary aim of this study is to compare, in terms of intubation time, vl,vl plus stylet and direct-laryngoscopy(dl) plus stylet combination with dl alone in obese patients.

patients who will be scheduled for surgeries requiring endotracheal intubation, with a body mass index (bmi) more than 30 kg/m2, will be included to this study. during preanesthetic visit (performed by an anesthesiologist not involved in this study) history of difficult intubation, measurement of common predictive indices for difficult intubation (bmi, thyromental distance, neck circumference, mallampati grade, interincisal \[or intergingival\] distances), and evaluation of status of dentition and neck movement will be noted. in the operating room, all patients will be connected to standard monitoring devices. anesthesia induction will be carried out according to our hospital obese patient anesthesia management protocol. then, after induction of anesthesia, the patients will be intubated one of four pre-defined protocols that will be determined via randomization during a preanesthetic visit by a person who is unfamiliar with the research protocol. primary hypothesis of this study is; using a video-laryngoscope plus stylet will reduce the time required to achieve successful tracheal intubation in obese patients.

Eligibility criteria:
inclusion criteria: * patients with a documented body mass index (bmi) of ≥ 30. * patients scheduled to undergo inpatient surgery procedures under general anesthesia. * willingness and ability to sign an informed consent document 18 - 80 years of age exclusion criteria: * patients who are deemed to be such a significant of an airway risk that they necessitate awake fiberoptic intubation * patients with a history of facial abnormalities, oral-pharyngeal cancer, or reconstructive surgery * emergency surgeries * pregnancy * any other conditions or use of any medication which may interfere with the conduct of the study.

Keywords: obese patients stylet procedures video laryngoscope first-attempt intubation
clinical research on the effect of aspirin on the disease free survival rate of esophageal carcinoma

Conditions: Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma

Summary: esophageal cancers are the seventh most common cancer in the world and one of the most common causes of cancer deaths. in some parts of china, the incidence of scc is among the highest in the world. despite surgery and adjuvant radiotherapy, the prognosis for scc patients was disappointing. there is therefore an urgent need for new prevention and treatment strategies. epidemiological investigations have found that about 25% of human tumors are associated with chronic inflammation caused by a variety of causes, and chronic inflammation activates nuclear transcription factors (nuclear factor,nf), induces gene and epigenetic changes such as dna methylation, tumor suppressor gene point mutations, and post-translational modification, and participates in the process of tumorigenesis. it has been noted that the long-term regularity of the use of non-steroidal anti-inflammatory drugs aspirin can reduce the incidence and mortality of a variety of tumors, including esophageal cancer. aspirin is the earliest, most extensive and common antipyretic analgesics and anti-rheumatism drugs used to play an anti-inflammatory role by inhibiting the synthesis of pgs. cox-2 is a key enzyme in the synthesis of pgs, so it is speculated that the anti-tumor effect of aspirin inhibits the pgs of cox and its inhibition.


Eligibility criteria:
inclusion criteria: * hospitalized patients with malignant tumors after radical operation of esophageal squamous cell carcinoma without merging other parts; pathological results are shown as all staging; immunohistochemical staining showed positive cox-2 expression; aspirin or other non-steroidal anti-inflammatory drugs have not been taken in the past; no abnormalities found in coagulation function; between the ages of 18-70 and five, gender is not limited; patient kps≥90, expected survival period of more than 6 months; patient signs informed consent statement; pregnant women with fertility must be negative in pregnancy trials. exclusion criteria: * severe coagulation dysfunction; severe liver, kidney and cardiac dysfunction; the lesion failed to completely remove; active digestive tract ulcers; reflux esophageal disease; allergies to aspirin or other drugs containing salicylic acid; history of asthma caused by salicylic acid salts or salicylate containing substances and non-steroidal anti-inflammatory drugs; cox-2 expression of immune tissue chemical staining weak or not expressed; wide transfer of the whole body; ever taken aspirin or other non-steroidal anti-inflammatory drugs; pregnant and lactating women.
effects of cerebellar tacs-itbs in ataxia

Conditions: Ataxia

Summary: ataxia refers to a group of neurological disorders characterized by impaired coordination and balance due to dysfunction in the cerebellum or its connections. traditional therapeutic approaches for ataxia have shown limited efficacy, prompting researchers to explore alternative interventions. non-invasive brain stimulation (nibs) techniques, such as transcranial magnetic stimulation (tms), transcranial direct current stimulation (tdcs), transcranial alternating current stimulation (tacs), and intermittent theta burst stimulation (itbs), have emerged as potential therapeutic options. the aim of this study is to investigate the combined effect of tacs-itbs on balance functions in ataxia disorders.


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of ataxia based on clinical assessment and/or neuroimaging findings. 2. stable medication regimen for at least four weeks prior to the study. 3. sufficient cognitive ability to understand and comply with study instructions. exclusion criteria: 1. history of seizures. 2. severe general impairment or concomitant diseases. 3. intracranial metal implants. 4. cardiac pacemaker. 5. pregnancy status.

Keywords: non invasive brain stimulation transcranial magnetic stimulation intermittent theta burst stimulation transcranial electrical stimulation transcranial alternating current stimulation exergaming
post-traumatic stress disease in health workers during covid-19 pandemia

Conditions: COVID; Post Traumatic Stress Disorder

Summary: the purpose of the questionnaire is to find risk factors for the development of post-traumatic stress disease (ptsd) in health workers during covid-19 pandemy.


Eligibility criteria:
inclusion criteria: * workers in health services, including phisicians, nurses, inhospital technicians and biologists

Keywords: covid-19
study of acetazolamide with temozolomide in adults with newly diagnosed or recurrent malignant glioma

Conditions: Malignant Glioma of Brain

Summary: this is a phase i study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (acz) and temozolomide (tmz). eligible patients must have histologically proven newly diagnosed, o6-methylguanine-dna methyltransferase (mgmt) methylated who grade iii or iv astrocytoma and be planning to undergo treatment with standard adjuvant tmz (after completing treatment with tmz and ionizing radiation (ir)). during this study, patients will receive daily oral acz with tmz. during each cycle, acz will be started on the day of tmz initiation and continued for a total of 21 days.


Eligibility criteria:
inclusion criteria: * histologically proven, newly diagnosed idh wildtype glioblastoma (gbm) that has a methylated mgmt promoter as assessed by the standardized institutional analysis. * patients are eligible if they had a prior low grade astrocytoma and there is subsequent histological evidence of a diagnosis of grade iii or iv tumor. * patients must be receiving tmz as part of their standard adjuvant treatment regimen following treatment with tmz and radiation. * patients must have a karnofsky performance ≥ 60%. * normal organ function as follows: * absolute neutrophil count (anc) ≥ 1.0 x 10\^9/ l * platelets ≥ 100 x 10\^9 / l * hemoglobin ≥ 8.0 g / dl * age 18 years or older. * kidney function (creatinine level within normal institutional limit, or creatinine clearance ≥ 60 ml/min/1.73 m2 for patients with creatinine level above institutional normal). * liver function (ast/alt \<2.5 x institutional upper limit of normal (uln), total bilirubin ≤ 1.5 times uln, inr within 1.5 times uln (or if receiving anticoagulant therapy an inr of ≤ 3.0 is allowed with concomitant increase in pt or an aptt ≤ 2.5 × control). * women able to become pregnant must have a negative pregnancy test within 30 days of registration. * patients must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * prior invasive malignancy that is not low-grade glioma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years. * active systemic infection requiring treatment, including any hiv infection or toxoplasmosis. * other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration. * systemic corticosteroid therapy, \>8 mg of dexamethasone daily (or equivalent) at study enrollment. * pregnant women are excluded from this study, where pregnancy is confirmed by a positive serum beta-hcg laboratory test. breast-feeding should be discontinued. * hypersensitivity to acetazolamide or sulfonamides.

Keywords: malignant glioma of brain acetazolamide temozolomide
bryostatin 1 in treating patients with myelodysplastic syndrome

Conditions: Leukemia; Myelodysplastic Syndromes

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of bryostatin 1 in treating patients with myelodysplastic syndrome.

objectives: i. determine the response rate of bryostatin 1 in patients with myelodysplastic syndrome. ii. determine the qualitative and quantitative toxic effects of bryostatin 1. iii. determine the duration of response and survival of patients receiving this therapy. outline: this is a two stage study. patients receive bryostatin 1 by continuous infusion over 72 hours every 14 days for 4 cycles. responding patients may continue treatment in the absence of disease progression or unacceptable toxicity. patients with complete response receive 2 additional cycles. patients with no response receive 4 additional cycles. patients are re-evaluated after every 4 cycles. projected accrual: 14 to 27 patients will be accrued within 2 years into this 2 stage study.

Eligibility criteria:
disease characteristics: histologically diagnosed refractory anemia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, refractory anemia with ringed sideroblasts, or chronic myelomonocytic leukemia with significant cytopenias of at least 4 weeks duration no more than 1 prior treatment for disease not eligible for allogeneic bone marrow transplantation if less than 60 years of age patient characteristics: age: 18 and over performance status: zubrod 0-2 life expectancy: at least 12 weeks hematopoietic: hematocrit less than 26% (or requiring transfusion) for at least 4 weeks absolute neutrophil count less than 1000/mm3 for at least 4 weeks platelet count less than 50/mm3 for at least 4 weeks hepatic: bilirubin less than 1.5 mg/dl transaminase less than 2.5 times upper limit of normal renal: creatinine less than 1.5 mg/dl creatinine clearance of at least 60 ml/min other: not pregnant or lactating fertile patients must use effective contraception while on study and for 100 days afterwards no uncontrolled or life-threatening infection prior concurrent therapy: biologic therapy: no concurrent immunotherapy no concurrent treatment with growth factors chemotherapy: at least 4 weeks since prior chemotherapy (8 weeks for mitomycin or nitrosourea) and recovered endocrine therapy: no concurrent use of steroids radiotherapy: at least 4 weeks since prior radiation therapy and recovered surgery: not specified

Keywords: refractory anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts refractory anemia with excess blasts in transformation chronic myelomonocytic leukemia de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes
effectiveness and cost-effectiveness of doin (conduction exercise) for chronic neck pain

Conditions: Chronic Neck Pain

Summary: a pilot multicenter randomized controlled trial will be conducted to evaluate the clinical effectiveness, cost-effectiveness, and safety of doin (conduction exercise) with acupuncture for chronic neck pain patients compared to acupuncture alone.

a pilot multicenter randomized controlled, parallel, assessor-blinded trial will be conducted to evaluate the comparative clinical effectiveness and cost-effectiveness of doin (conduction exercise) with acupuncture for chronic neck pain patients with acupuncture alone as assessed by pain and functional disability scales, monitor its safety, and assess the feasibility of and serve as the basis for a full-scale, multicenter trial.

Eligibility criteria:
inclusion criteria: * onset of at least 6 months previous for neck area pain * current neck area pain of numeric rating scale (nrs) 5 or higher * patients who have agreed to voluntarily participate in the clinical trial and given written informed consent exclusion criteria: * pathologies of non-spinal or soft tissue origin or high severity which may cause neck or radiating arm pain (e.g. malignant tumor, spinal infection, inflammatory spondylitis, fibromyalgia, rheumatic arthritis, gout) * progressive neurologic deficit or severe neurologic symptoms (e.g. cauda equina syndrome, progressive muscle weakness) * other chronic diseases which may interfere with treatment effect or interpretation of results (e.g. cardiovascular disorder, renal disease, diabetic neuropathy, dementia, epilepsy) * current intake of steroids, immunosuppressant medicine, psychiatric medicine or other medication which may interfere with treatment results * patients considered unsuitable or unsafe to receive acupuncture (e.g. patients with hemorrhagic diseases, blood clotting disorders, history of anti-coagulation medicine intake, severe diabetes with high risk of infection, severe cardiovascular diseases) * patients who were treated with invasive interventions such as acupuncture or injections, or with medicine that may potentially influence pain such as nsaids (nonsteroidal antiinflammatory drugs) within the past week * history of cervical surgery within the past 3 months * pregnancy or plans of pregnancy * severe psychopathy * participation in other clinical studies * inability to give written informed consent * other reasons rendering trial participation inappropriate as judged by the researchers

Keywords: neck pain disability evaluation costs and cost analysis doin exercise therapy acupuncture
immune-modulated study of selected small molecules (gefitinib, azd9291, or selumetinib + docetaxel) or a 1st immune-mediated therapy (imt; tremelimumab) with a sequential switch to a 2nd imt (medi4736) in patients with locally advanced or metastatic non-small-cell lung cancer

Conditions: Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

Summary: primary objective: to assess the efficacy of various sequences of either a small molecule or an imt (imt-a) followed by a imt-b (medi4736) .

this is a multi-arm, multi-cohort, phase iia, open-label study of selected small molecules (gefitinib, azd9291, or selumetinib + docetaxel) or 1st imt (hereafter referred to as imt-a; tremelimumab) followed by sequential switch to a 2nd imt (hereafter referred to as imt-b; medi4736) in locally advanced or metastatic nsclc (stage iiib-iv). patients will be enrolled concurrently into multiple cohorts.

Eligibility criteria:
inclusion criteria: * provision of archived tumor tissue sample and mandatory tissue biopsy * patients must have either histologically or cytologically documented nsclc who present with locally advanced or metastatic stage iiib-iv disease * life expectancy ≥12 weeks * patients must have measurable disease and at least 1 lesion not previously irradiated * world health organization (who) performance status of 0 or 1 exclusion criteria: * mixed small cell and nsclc histology * prior exposure to any anti-pd-1 or anti-pd-l1 antibody

Keywords: lung cancer; nsclc
preventing loss of weight, fat free mass and activities of daily living

Conditions: Hip Fracture; Arthrosis

Summary: malnutrition of elder orthopaedic patients leads to weight loss and loss of fat free mass. changes in the individual's nutritional status and body composition may adversely affect the patient's postoperative level of activity. aim. thus, the purpose of the present study is to report changes in postoperative weight, ffm and functions vital to daily living in a group of elder orthopaedic patients that were actively involved in their nutritional care during the hospital stay.

malnutrition of elder orthopaedic patients leads to weight loss and loss of fat free mass. changes in the individual's nutritional status and body composition may adversely affect the patient's postoperative level of activity. aim. thus, the purpose of the present study is to report changes in postoperative weight, ffm and functions vital to daily living in a group of elder orthopaedic patients that were actively involved in their nutritional care during the hospital stay. method. the study comprises 253 patients aged 65+ and admitted either for hip- or knee replacement or with a fractured hip. following a quasi-experimental design, 142 patients were allocated to the control group and 109 patients to the intervention group. the intervention programme focused on patients' involvement in their nutritional care. body composition by bio impedance and functional status by a standard chart were assessed at admission and four months postoperatively.

Eligibility criteria:
inclusion criteria: * aged 65 and above admitted either for elective hip- or knee replacement or acute with a fractured hip were allocated to the study. patients included in the study were to stay in hospital for more than 7 days and agree on coming to the outpatient clinic for a follow-up four months after surgery. exclusion criteria: * patients who refused to participate, patients were not able to understand the instructions,or received dietary treatment due to dm. patients who suffered from cancer, gastrointestinal disorders or were undergoing steroid treatment. in addition, patients who were unable to participate due to serious heart disorders; or were transferred to intensive or cardiac units after surgery and did not return to the ward.

Keywords: activities of daily living elderly nutrition postoperative hip fractures hip replacement knee replacement